Objective-Therapeutic arteriogenesis, that is, expansive remodeling of preexisting collaterals, using single-action factor therapies has not been as successful as anticipated. Modulation of factors that act as a master switch for relevant gene programs may prove more effective. Transcriptional coactivator p300-CBP-associated factor (PCAF) has histone acetylating activity and promotes transcription of multiple inflammatory genes. Because arteriogenesis is an inflammationdriven process, we hypothesized that PCAF acts as multifactorial regulator of arteriogenesis. Approach and Results-After induction of hindlimb ischemia, blood flow recovery was impaired in both PCAF −/− mice and healthy wild-type mice treated with the pharmacological PCAF inhibitor Garcinol, demonstrating an important role for PCAF in arteriogenesis. PCAF deficiency reduced the in vitro inflammatory response in leukocytes and vascular cells involved in arteriogenesis. In vivo gene expression profiling revealed that PCAF deficiency results in differential expression of 3505 genes during arteriogenesis and, more specifically, in impaired induction of multiple proinflammatory genes. Additionally, recruitment from the bone marrow of inflammatory cells, in particular proinflammatory Ly6C 
P eripheral arterial occlusive disease is a leading cause of morbidity and mortality. Blood flow to ischemic tissues in the affected limb can be restored by distinct processes, 1 namely vasculogenesis, angiogenesis, and arteriogenesis, of which arteriogenesis, the remodeling of preexisting collateral arterioles into larger arteries, has the greatest impact. 2 Effective arteriogenesis requires coordination of multiple events. Arteriogenesis is triggered by an increase in fluid shear stress across preexisting collaterals cross-connecting adjacent arterial trees, which is caused by a pressure gradient created by occlusion or atherosclerotic stenosis of one of the trees. This leads to activation of the endothelial cells and adjacent vascular smooth muscle cells (VSMCs) of the collateral wall. Induction of adhesion molecules, cytokines, and chemokines then follows as the first step of an inflammatory cascade essential for arteriogenesis. Recruitment of leukocytes from blood and bone marrow follows, in particular monocytes, [3] [4] [5] [6] and CD4 + , CD8 + , and regulatory T cells and natural killer cells. [7] [8] [9] [10] [11] These cells infiltrate into the perivascular space around collaterals and release additional paracrine signaling molecules and growth factors. Subsequent degradation and reorganization of the extracellular matrix by released matrix metalloproteases (MMPs), including MMP2 and MMP9, create space required for expansive remodeling of the preexisting collaterals. Proliferation of collateral endothelial cells, VSMCs, and fibroblasts is stimulated, resulting in an increased anatomic lumen diameter. All of the steps described above underline the crucial role of inflammation in effective arteriogenesis. Although stimulation of collateral remodeling is considered as a promising therapeutic alternative to surgical interventions, clinical trials aimed at modulating individual growth factors or cytokines have thus far not been as successful as anticipated. 12 Now, we know that the coordinated inflammatory and immune modulatory processes driving collateral growth are multifactorial and too complex to be modulated by therapeutics that target a single gene or pathway. In contrast, modulation of a factor that acts as a master switch for multiple relevant gene programs may be a more effective strategy to augment arteriogenesis.
A protein with such master switch potential is p300-CBPassociated factor (PCAF), a transcriptional coactivator with intrinsic histone acetyltransferase activity. PCAF acetylates histones H3 and H4, but there is also increasing evidence that PCAF modulates nonhistone proteins, [13] [14] [15] [16] including hypoxiainducible factor 1α 17 and Notch. 18 Furthermore, the histone acetylating activity of PCAF is essential for nuclear factor κB (NF-κB)-mediated gene transcription 19 and facilitates inflammatory gene regulation. 20 Because arteriogenesis is an inflammatory-like process, we hypothesized that PCAF acts as master switch that stimulates multiple inflammatory processes important for collateral remodeling.
Recently, it was shown in a large patient population study (>3000 individuals) 21 that a variation in the promoter region of PCAF is associated with coronary heart disease-related mortality. 22 In support of this observation, we recently demonstrated a role for PCAF in vascular remodeling in a mouse model for reactive stenosis. However, whether PCAF participates in arteriogenesis has not yet been investigated.
In the present study, we investigated the contribution of PCAF to postischemic neovascularization in a hindlimb ischemia (HLI) model, 23 using PCAF-deficient (PCAF −/− ) mice. When studying arteriogenesis in a knockout model, it is possible that the gene deletion may affect vascular development in the embryo, including collaterogenesis, thus affecting the number of collaterals available for remodeling after an occlusive event in the adult. To investigate whether observed effects were caused by differences in arteriogenesis, in the native collateral circulation or a combination of both, we examined the preexisting collateral density as well as the effect of administration of the PCAF inhibitor Garcinol to wild-type (WT) mice after induction of HLI. We also studied gene expression and leukocyte recruitment in PCAF −/− and WT mice after induction of HLI to examine potential mechanisms by which PCAF regulates arteriogenesis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

PCAF Contributes to Collateral Remodeling
PCAF
−/− mice showed impaired blood flow recovery after HLI ( Figure 1A and 1B) . Postoperative blood flow was decreased to ≈6% of blood flow in the contralateral limb in both groups, with a trend toward reduced blood flow in PCAF −/− mice compared with WT mice ( Figure 1C ; P=0.07). Thereafter, blood flow recovery in PCAF −/− mice was reduced and did not recover completely before termination at 28 days. Moreover, PCAF −/− mice showed significantly more necrotic toe nails than WT mice (PCAF −/− 2.9±0.6 versus WT 0.45±0.2; P<0.001; Figure 1D ). No autoamputation of hindlimb digits was observed in either group. The reduced blood flow recovery in PCAF −/− mice was confirmed by quantification of smooth muscle α-actin positive (αSMA + ) vessels in the adductor muscle group, 28 days after HLI ( Figure 1E ). Both the number of αSMA + vessels ( Figure 1F ) and the diameter of αSMA + vessels ( Figure 1G  and 1H Figure 1G and 1H) . Thus, PCAF deficiency leads to reduced arteriogenesis after induction of HLI.
To assess whether the reduction in blood flow recovery in PCAF −/− mice was caused by reduced collateral remodeling or by fewer preexisting collaterals, we performed 2 additional experiments. First, we inhibited PCAF by pharmacological intervention with Garcinol to rule out any effects on number of preexisting collaterals in the PCAF −/− mice. In WT mice, local PCAF inhibition by Garcinol resulted in reduced blood flow restoration compared with the empty pluronic gel control group (Figure 2A and 2B) . Second, the preexisting vascular bed of PCAF −/− and WT mice was assessed in the pial circulation using an arterial vascular casting ( Figure 2C ). Pial collateral density in PCAF −/− mice was reduced by 11% compared with WT mice, reflecting a moderate but significant contribution of PCAF in determining the abundance of the native collateral circulation (Figure 2D and 2E; P=0.02). This was in agreement with the trend toward decreased blood flow perfusion in PCAF −/− mice directly after HLI.
PCAF Is Required for In Vitro Inflammatory Response
We investigated the role of PCAF in the inflammatory response of multiple cell types, given the above evidence for decreased collateral remodeling and the known involvement of these cells in arteriogenesis. Analysis of circulating cells in a whole blood lipopolysaccharide (LPS) stimulation assay showed dose-dependent increase of tumor necrosis factor α (TNFα) in blood from WT mice, which was significantly reduced in blood from PCAF −/− mice ( Figure 3A) . Next, the splenic cell reservoir was subjected to LPS stimulation and pharmacological PCAF inhibition with Garcinol. LPS (300 ng/mL)-stimulated monocyte chemotactic protein (MCP)-1 levels of splenocytes from both PCAF −/− mice (63±32 pg/mL) and WT splenocytes treated with 20 μmol/L Garcinol (195±35 pg/mL) were both significantly reduced in comparison with WT splenocytes (372±13 pg/mL; P=0.005 and P=0.04, respectively; Figure 3B ). Also the inflammatory phenotype of PCAF −/− VSMCs was assessed. Similar to the splenocyte stimulation, MCP-1 levels were markedly reduced after LPS (0.1 ng/mL) stimulation of PCAF −/− VSMCs (689±49 pg/mL) and WT VSMCs when exposed to 15 μmol/L Garcinol (3087±284 pg/mL) compared with untreated WT VSMCs (4175±264 pg/mL; P<0.001 and P=0.049, respectively; Figure 3C ). In addition, upregulation of MCP-1 mRNA was significantly reduced by 53% in PCAF −/− VSMCs ( Figure 3D ; P=0.01). To exclude nonspecific effects of Garcinol, these experiments were repeated in WT VSMCs treated with siRNAs against PCAF mRNA instead of Garcinol. Transfection with siRNAs targeting PCAF mRNA efficiently decreased PCAF mRNA expression by 61% and, like Garcinol, inhibited MCP-1 production ( Figure IA -IC in the online-only Data Supplement).
PCAF Modulates Postischemic Gene Regulation
PCAF staining showed enhanced expression in cells of large developing collaterals in the adductor muscle group compared with surrounding skeletal muscle ( Figure 4A ). To study differential gene expression after HLI between PCAF −/− and WT mice, total RNA isolated from the adductor muscle group was used in a whole-genome expression analysis using Illumina Beadchips. Statistical analysis by SAM on t1/t0 avg ratios identified 1963 genes with a significant lower ratio and 1542 genes with a higher ratio in PCAF −/− relative to WT mice (q<5%), indicating that PCAF exhibits a large effect on gene transcription after HLI ( Figure 4B ). Table I in the online-only Data Supplement shows the top 50 genes with impaired upregulation in PCAF −/− mice compared with WT mice, including MMP9, critical in matrix degradation required for collateral artery expansion. Because PCAF has been shown to regulate inflammatory gene transcription, we selected inflammatory genes that were significantly regulated (Table II in showing a more pronounced induction in WT mice compared with PCAF −/− mice were genes encoding cytokines chemokine (C-X-C motif) receptor 1 (CXCR1), chemokine (C-C motif) ligand 9 (CCL9), and TNFα, chemokine receptor CXCR1, transcription factor interferon regulatory factor 7 (IRF7), TNF receptor-associated factors TRAF2 and TRAF3, TNF receptor-associated protein TRAP1 and members of the TNF receptor superfamily TNFRSF19 and TNFRSF11a (also known as RANK). The total of inflammatory genes with greater induction in PCAF −/− mice was much smaller than the number of genes more strongly induced in WT, and included inhibitors of the NF-κB pathway like NFKBIA and NKIRAS1. Aberrant regulation of several relevant regulated factors (MMP9, TNFα, CCL9, CXCL12, and IRF7) was confirmed using real-time quantitative polymerase chain reaction ( Figure 4C -4G).
PCAF Deficiency Alters Leukocyte Recruitment
We quantified leukocyte subtypes that are involved in arteriogenesis, including T cells (helper CD4 + , cytotoxic CD8 + , and regulatory T cells) and natural killer cells, and subtypes, which have not been previously implicated in arteriogenesis, including B cells and dendritic cells. Blood samples from before (t0) and 1 day after (t1) HLI were analyzed by fluorescence To investigate the migratory behavior of the leukocyte subtypes, the spleen, bone marrow, and lymph nodes were harvested from both mouse strains before (t0) and 1 day after (t1) HLI. Compared with WT mice, we observed reduced numbers of dendritic cells in the draining inguinal lymph nodes of PCAF −/− mice after HLI. Accordingly, the fraction of dendritic cells expressing the costimulatory molecule CD86 + was smaller in the draining lymph nodes of PCAF −/− mice. Furthermore, nearly all tested leukocyte subtypes were increased in the bone marrow of PCAF −/− mice compared with WT mice, including CD4 + and CD8 + T cells, natural killer cells, and dendritic cells, suggesting that these subpopulations are retained in the bone marrow of PCAF −/− mice during recovery after HLI ( Figure  IIIA -III(I) in the online-only Data Supplement).
Because monocytes play a key role in arteriogenesis and are among the first leukocytes recruited to remodeling collaterals, we evaluated different monocyte populations in blood, spleen, and bone marrow. After HLI, the absolute number of circulating monocytes in WT mice was equal to baseline numbers, but monocytes in PCAF −/− mice significantly decreased compared with baseline (PCAF −/− 0.13±0.05 versus WT 0.37±0.02×10 6 / mL; P=0.002; Figure 5A ). In WT mice, the monocyte population increased in the spleen and decreased in the bone marrow after HLI. In contrast, bone marrow monocytes in PCAF −/− mice increased compared with baseline and were significantly higher after HLI compared with WT mice (Figure 5B and 5C ). The differences in monocyte numbers were caused mainly by the specific subtype of proinflammatory Ly6C hi monocytes ( Figure 5D-5F ). The activation state of total and Ly6C hi monocytes did not differ between the 2 strains, measured by mean fluorescent intensity of the adhesion molecule CD11b (Figure 5G and 5H) .
Finally, we assessed the number of monocytes/macrophages in the adductor muscle group by fluorescent staining with antibodies against anti monocyte/macrophage antibody 2 and αSMA ( Figure 6A ). Although PCAF −/− mice showed a significant increase in anti monocyte/macrophage antibody 2-positive cells 24 hours after HLI, the increase in WT mice was significantly higher (PCAF −/− 3.2±0.35 versus WT 6.0±0.43 / section; P=0.001; Figure 6B ). Differences were most evident in the perivascular space of remodeling collaterals (PCAF −/− 1.4±0.16 versus WT 3.5±0.76/section; P=0.01; Figure 6C ).
Discussion
We demonstrate that blood flow recovery after induction of HLI is strongly impaired in PCAF −/− mice, in association with reduced expansive remodeling of collaterals. Furthermore, local PCAF inhibition by Garcinol in WT mice also reduces recovery, indicating that PCAF is directly required for normal arteriogenesis. PCAF gene deficiency results in a repressed in vitro inflammatory response in many cell types known to Figure 2 . Arteriogenesis after pharmacological inhibition of p300-CBP-associated factor (PCAF) and assessment of the preexisting collateral bed in PCAF −/− mice. A, Representative laser Doppler perfusion imaging (LDPI) images of paws directly and 7 days after induction of hindlimb ischemia in the left limb, by single electrocoagulation of the femoral artery. In wild-type (WT) mice, pluronic gel with or without 25 mg/mL Garcinol was applied topically to the adductor muscle before skin closure. High blood flow is displayed in red. B, Quantification of LDPI measurements of WT mice treated with Garcinol or control over time. C, Representative images of the pial circulation in PCAF −/− and WT mice. White asterisks indicate collateral arteries between anterior, middle, and posterior cerebral arteries (ACA, MCA, and PCA, respectively). After exsanguination and maximal dilation of the dorsal cerebral circulation, Microfil was used as a casting agent, after which the whole brain was fixated in 4% PFA. D, Pial collateral density was calculated in PCAF −/− and WT mice by dividing the sum of ACA to MCA, ACA to PCA, and MCA to PCA by the surface area of the cerebral hemispheres. E, Region of the brain used for calculation of pial density. Areas were excluded when they were damaged, had poor filling with Microfil, or were otherwise uncountable. NS indicates nonsignificant. All values are presented as the mean±SEM. *P<0.05, PCAF −/− vs WT.
be involved in arteriogenesis. One day after induction of HLI, 3505 genes are differentially regulated in the adductor muscle group of PCAF −/− mice compared with WT mice. Additionally, recruitment of different proarteriogenic leukocyte subtypes in PCAF −/− mice, in particular inflammatory monocytes, is significantly impaired at this time. Therefore, our data demonstrate that PCAF plays a key role in postischemic arteriogenesis.
Compared with WT mice, PCAF −/− mice showed an impaired blood flow recovery after HLI. Our findings suggest that 2 deficiencies caused by a lack of PCAF are involved. First, the expansive remodeling of αSMA + arterioles at the center of the adductor muscle group, of which most are collaterals, was reduced by 53% in PCAF −/− mice compared with WT mice. Correspondingly, local application of PCAF inhibitor Garcinol in healthy WT mice also resulted in impaired blood flow recovery compared with control animals. Hence, PCAF has a major impact on arteriogenesis. Second, we observed that the density of native preexisting collaterals in the pial circulation of PCAF −/− mice was reduced by 11%. Even changes of this magnitude have significant effects on collateral-dependent perfusion of tissue downstream from an arterial obstruction. [24] [25] [26] Previous studies have shown that genetic-dependent variation in collateral number in the cerebral pial circulation is shared, at least qualitatively, by similar differences in collateral density in other tissues. [24] [25] [26] Accordingly, we also observed a trend toward a decrease in blood flow directly after induction of HLI in PCAF −/− mice. In mice, the density of the native collaterals in tissues varies widely among strains from differences in genetic background. [24] [25] [26] Hence, besides collateral remodeling, genetic PCAF deficiency also contributes to reduced formation of the collateral circulation, which occurs during embryonic development.
In a clinical setting, the outcome after an ischemic event varies among individuals, and differences in abundance of the native collateral circulation have also been reported in patients. 27, 28 Moreover, a previous study found that the −2481G allele in the promoter region of the PCAF gene associates with an increased risk of mortality in patients with coronary heart disease, 22 which further supports our findings that PCAF deficiency impairs collateral function.
For PCAF to serve as a master switch in collateral remodeling, it needs to impact multiple critical phases in the process, namely activation of the endothelium and vessel wall, leukocyte recruitment, matrix degradation, and arteriolar expansion. We examined gene expression in the adductor muscle group containing remodeling collaterals in the initial phase after HLI. More than 3500 genes were differentially regulated between PCAF −/− and WT mice. This suggests that PCAF impacts expression of a large number of genes activated in this setting. More specifically, PCAF −/− mice showed impaired induction of multiple proarteriogenic and proinflammatory genes, including MMP9 and chemokines CXCL12 (SDF1) and CCL9.
MMP9 is critical in degradation and remodeling of the extracellular matrix allowing cell migration and outward expansion of the collaterals and, thus, effective arteriogenesis. 29 CXCL12 is elevated in ischemic skeletal muscle of patients with critical limb ischemia 30 and acts as chemoattractant for CXCR4 + cells, including leukocytes and progenitor cells. CXCL12-mediated recruitment of bone marrow-derived cells to ischemic tissues results in enhanced neovascularization. 31, 32 Also CCL9, which is a strong chemoattractant for bone marrow-derived cells, 33 is upregulated after muscle injury. 34 In addition, PCAF −/− mice showed impaired induction of multiple factors related to the proinflammatory TNFα pathway. 35 TNFα −/− mice have reduced collateral artery perfusion, 36 and anti-TNFα therapy attenuates arteriogenesis. 37 Thus, reduced TNFα expression in PCAF −/− mice likely contributes to the impaired arteriogenesis in these mice. Our data suggest that PCAF regulates many factors that have previously been described, thus, playing an important role in both inflammation and arteriogenesis. 38 It should be noted that RNA was isolated from the adductor muscle group as a whole 38 and not from the embedded collateral arteries alone, as was described previously. 39 In that report, a whole-genome microarray analysis was performed on collaterals microdissected from the gracilis muscle 24 hours after HLI. Here, we found exceedingly more differentially expressed genes, then the 404 genes that were found upregulated in gracilis collaterals of WT mice. 39 Using the entire adductor muscle group for microarray analysis, not only the collaterals but also infiltrating leukocytes and surrounding nonvascular tissues were included in these analyses.
As discussed in the introduction, an inflammatory-like process plays a role in all stages of arteriogenesis. To investigate the impact of PCAF on the inflammatory response of the different cell types involved in arteriogenesis, we studied circulating cells in whole blood, splenic leukocytes and VSMCs in vitro. PCAF is critical for the regulation of transcription factor NF-κB, which consists of a p65 and p50 subunit bound to inhibitory proteins in the cytoplasm. On stimulation NF-κB is translocated to the nucleus and regulates the expression of multiple genes, . Data are presented as the fold change in expression between day 1 (t1) and average preoperative baseline levels (t0), generating t1/t0 avg ratios. Red indicates increased and green indicates reduced expression relative to average baseline levels. The pie graph illustrates a significant decrease of 1963 genes (green) and increase of 1542 (red) genes in PCAF −/− relative to WT mice. C-G, Microarray validation by real-time quantitative polymerase chain reaction of a selection of relevant regulated inflammatory factors matrix metalloproteinase 9 (MMP9), tumor necrosis factor α (TNFα), chemokine (C-C motif) ligand 9 (CCL9), interferon regulatory factor 7 (IRF7), chemokine (C-X-C motif) ligand 12 (CXCL12), and its receptor chemokine (C-X-C) receptor 4 (CXCR4) (H). The height of the bars represents the ratio of expression in PCAF −/− (black bars) and WT (white bars) mice at day 1 over day 0. Cts were normalized against Cts of HPRT1. All values are presented as the mean±SEM. *P<0.05, **P<0.01, PCAF −/− vs WT. αSMA indicates smooth muscle α-actin; and PCAF, p300-CBP-associated factor.
including TNFα and MCP-1. 20, 40 PCAF binds to the NF-κB p65 subunit and activates NF-κB-related inflammatory gene expression. 19, 20 We clearly demonstrate that PCAF deficiency results in decreased production of proinflammatory cytokines by multiple cell types after stimulation with LPS. LPS-stimulated whole blood from PCAF −/− mice produced less TNFα than blood from WT mice, indicating a reduced inflammatory phenotype of circulating cells. Also PCAF −/− cells isolated from the spleen, one of the major leukocyte reservoirs, showed a reduced inflammatory response compared with splenocytes from WT mice. PCAF −/− VSMCs produced less MCP-1 than WT VSMCs in response to LPS, which would favor reduced monocyte recruitment and, therefore, reduced VSMC proliferation, which is essential for collateral remodeling. We obtained similar results using either Garcinol or PCAF-specific siRNA knockdown in WT VSMCs, thus excluding effects of any preexisting differences in PCAFdeficient cells. Our data correspond with a report that TNFα-induced NF-κB activity increases in human airway smooth muscle cells overexpressing PCAF 41 and provide strong evidence for a wide effect of PCAF on inflammatory gene transcription.
The p65 subunit of NF-κB recruits coactivator PCAF and activates NF-κB-mediated gene transcription. In contrast, the NF-κB p50 subunit lacks the transcriptional activation domain and inhibits gene transcription. 42 Mice deficient of the NF-κB p50 subunit showed enhanced blood flow recovery after HLI as the result of increased monocyte recruitment to the perivascular space of collaterals. 43 Whereas arteriogenesis and monocyte recruitment are enhanced by NF-κB activation in NF-κB p50 −/− mice, reduced regulation of the NF-κB p65 subunit in PCAF −/− mice could likely explain the impaired arteriogenesis by inhibition of monocyte recruitment. In WT mice, the monocyte population increased in the spleen and decreased in the bone marrow after HLI. This is in line with earlier reports that monocytes are mobilized from the bone marrow after HLI. 44 In that report, the proarteriogenic potential of monocytes was described to originate from a specific proinflammatory subtype, which is characterized by high expression of Ly6C. These Ly6C hi monocytes are recruited in the early stage of collateral remodeling, 44, 45 and our data confirm that they are mobilized from the bone marrow in WT mice. In contrast, recruitment of monocytes proved to be severely impaired in PCAF −/− mice. PCAF −/− mice showed reduced numbers of circulating monocytes after HLI, particularly reduced numbers of Ly6C hi monocytes. Whereas monocytes migrated away from the bone marrow in WT mice, PCAF −/− mice showed an increase in bone marrow monocytes, suggesting a defect in monocyte mobilization. Concomitantly, 24 hours after HLI fewer monocytes were recruited to the collaterals in PCAF −/− mice. Monocytes stimulate arteriogenesis by secretion of growth factors and degradation of extracellular matrix at the site of collateral remodeling. Therefore, the lack of monocyte accumulation along collaterals likely contributes to the impaired arteriogenesis in PCAF −/− mice. Besides monocytes, PCAF also affected numerous other leukocyte subtypes. In PCAF −/− mice, we demonstrated decreased numbers of circulating leukocytes involved in arteriogenesis, like T cells 46 (predominantly activated CD4 + T cells), 7,11 natural killer cells, 11 and regulatory T cells, 9, 10 and also in those cells that have not previously been implicated in arteriogenesis, including B cells. Furthermore, fewer dendritic cells were found in draining inguinal lymph nodes compared with WT mice, where the interaction between antigen-presenting dendritic cells and T cells takes place. Interestingly, nearly all subtypes were increased in the bone marrow of PCAF −/− mice, after HLI. This indicates that PCAF deficiency interferes with recruitment of proarteriogenic leukocytes from the bone marrow reservoir. 47 In conclusion, PCAF −/− mice demonstrated impaired collateral remodeling after HLI, together with a reduction in the number of native preexisting collaterals present before arterial obstruction. PCAF deficiency resulted in altered expression of a large number of genes, including those in immune and inflammatory pathways, and an attenuated inflammatory response in multiple cell types involved in arteriogenesis. These findings indicate that PCAF is a key regulator in postischemic blood flow recovery by impacting the inflammatory processes required for robust arteriogenesis. −/− mice after hindlimb ischemia (HLI). A, Immunohistochemical staining on fresh frozen sections of the adductor muscle group from PCAF −/− and wild-type (WT) mice 1 day after HLI, using antiαSMA (red) and anti-monocyte/macrophage antibody 2 (MOMA2) (green) antibodies. Cell nuclei were labeled with DAPI (blue). Scale bars=100 μm. B and C, Quantification of MOMA-2-positive cells in the adductor muscle group of PCAF −/− and WT before (t0) and 1 day after (t1) HLI. Monocytes were quantified from ≥6 consecutive sections per mouse and expressed as the number of MOMA-2-positive cells per section and as the number of MOMA-2-positive cells in the perivascular space of αSMA + vessels per section. *P<0.05, **P<0.01. αSMA indicates smooth muscle α-actin; and PCAF, p300-CBP-associated factor.
